Cagrilintide is a 37-amino-acid synthetic analog of human amylin (islet amyloid polypeptide, IAPP), modified with a C18 fatty diacid acylation that enables reversible, non-covalent binding to serum albumin
Injection Site Selection For subcutaneous injections, common sites include the abdomen at least two inches from the navel, front and outer thighs, and back of upper arms
Switching from Semaglutide GLP-1 to tirzepatide can offer enhanced weight loss results, improved medication adherence, and better management of comorbidities
Market Expansion: Initially approved for T2D, higher-dose versions of these peptides (e.g., semaglutide for obesity) have demonstrated remarkable efficacy in weight management, legitimizing pharmacology as a core treatment for obesity